Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 6/20 | 0.32 |
| ▸ | CNR2 | P34972 | 6/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16472204 | 0.84 | PDE4A (0.37) | ELANEPDE4AKCNH2CNR1CNR2 | |
| SCHEMBL12500821 | 0.78 | PDE4A (0.37) | ELANEPDE4AKCNH2CNR1CNR2 | |
| SCHEMBL411033 | 0.73 | ELANE (0.36) | ELANEDYRK1A | |
| SCHEMBL414164 | 0.73 | ELANE (0.42) | ELANEPDE4AKCNH2DYRK1AFEN1 | |
| SCHEMBL415255 | 0.73 | ELANE (0.42) | ELANEPDE4AKCNH2DYRK1AFEN1 | |
| SCHEMBL15640343 | 0.73 | LMNA (0.48) | PDE4AKCNH2CNR1CNR2 | |
| SCHEMBL416093 | 0.70 | L3MBTL1 (0.35) | ELANEPDE4AKCNH2DYRK1AFEN1 | |
| SCHEMBL413483 | 0.70 | KMT2A (0.41) | ELANEPDE4AKCNH2FEN1IDO1 | |
| SCHEMBL12500880 | 0.68 | PTGDR2 (0.47) | CNR2 | |
| SCHEMBL12147051 | 0.68 | KDM4E (0.46) | PDE4AKCNH2CNR1CNR2FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011806-A1 | PYRAZOLE DERIVATIVES AS ERK INHIBITORS | KINENTIA BIOSCIENCES LLC (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011806-A1 | PYRAZOLE DERIVATIVES AS ERK INHIBITORS | MAPK1, MAP3K1, MAP3K5 | ELANE 2981/4885PDE4A 2509/4885KCNH2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.